Yahoo Finance • 3 months ago
NewAmsterdam Pharma (NASDAQ:NAMS) Second Quarter 2024 Results Key Financial Results Net loss: US$39.0m (loss widened by 1.9% from 2Q 2023). US$0.41 loss per share. earnings-and-revenue-growth All figures shown in the chart above are for... Full story
Yahoo Finance • 6 months ago
NewAmsterdam Pharma N.V. -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first... Full story
Yahoo Finance • 7 months ago
NewAmsterdam Pharma N.V Enrollment to continue to the end of April to accommodate strong patient and site interest NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “... Full story
Yahoo Finance • 12 months ago
Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs Successful fundraising d... Full story
Yahoo Finance • 12 months ago
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial evaluating obicetrapib in patients with early Alz... Full story
Yahoo Finance • last year
NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story
Yahoo Finance • last year
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM prot... Full story
Yahoo Finance • last year
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medi... Full story
Yahoo Finance • last year
NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story
Yahoo Finance • last year
NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for... Full story
Yahoo Finance • last year
Dualyxraises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001,targeting TNFR2, as well as its pipeline of Treg candi... Full story
Yahoo Finance • 2 years ago
-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options -- -- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and MIAMI, April 24, 2023 (GLOBE NEWSWIR... Full story
Yahoo Finance • 2 years ago
Forbion’s largest fundraising to date€750 million raised in the final close of the Forbion Ventures Fund VI €600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Fo... Full story
Yahoo Finance • 2 years ago
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfo... Full story
Yahoo Finance • 2 years ago
-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 -- -- Announ... Full story
Yahoo Finance • 2 years ago
NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfor... Full story
Yahoo Finance • 2 years ago
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfor... Full story
Yahoo Finance • 2 years ago
-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) -- -- Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm -- -- Favorable safety and tolerability -- -- Data s... Full story